Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
PARSIPPANY, N.J., June 01, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
